CEO of drugstore.com nominated for Times board of directors
NEW YORK The New York Times Co. last week named Robert Denham, a partner in the Munger, Tolles & Olson law firm, and Dawn Lepore, chief executive officer and chairman of drugstore.com, to stand as nominees for election to the company’s Board of Directors at the 2008 annual meeting of stockholders on April 22.
“We are delighted that these two exceptional individuals have agreed to be nominees for election by our shareholders,” stated Arthur Sulzberger, Jr., chairman of The New York Times Co. “Bob Denham brings stellar financial and legal experience as well as a broad strategic perspective to our Board. Dawn Lepore is highly respected with deep experience in the digital sphere and strong relationships in both Silicon Valley and the Seattle technology community. The skills, expertise and leadership qualities of these two nominees will greatly benefit our company during this time of tremendous change in the media world.”
Isma Benattia named Wyeth Consumer Healthcare head of global R&D
MADISON, N.J. Wyeth Consumer Healthcare announced that Isma Benattia has been named executive vice president of Global Research and Development, effective immediately.
In her new role, Benattia will be in charge of bringing new products to market and managing regulatory necessities regarding Wyeth’s over-the-counter products.
Benattia has served at Wyeth Pharmaceuticals since 2003, where she most recently was vice president in charge of Global Labeling. She previously held the position of executive medical director of neuroscience, where she played a leading role in managing scientific and regulatory issues involving Effexor, Wyeth’s second largest brand in terms of global revenue.
Prior to joining Wyeth, Benattia led global clinical programs for major products at Pfizer and Eli Lilly. She holds Master’s degrees in Pharmacology and Psychotropic Drugs; Methodology of Clinical Research and Medical and Marketing Management.
Study shows Relacore may reduce acne flare-ups
NEW YORK Carter Reed on Friday released studies that suggests its dietary supplement diet aid Relacore may be useful in reducing acne flare-ups.
“One of the reasons Relacore has been so successful is because people buy it along with other diet pills or to use in conjunction with any sensible diet and exercise plan,” stated Gina Daines, Carter-Reed’s director of marketing. “Now when it comes to acne, we’re seeing the same phenomenon—those who buy popular anti-acne treatments, like Proactive, are picking up a bottle of Relacore to expand and complete their anti-acne regimen, using Relacore to help prevent the stress-related increase, duration, frequency and severity of acne flare-ups.”